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A B S T R A C T
Background and aims: Use of non-prescribed drugs during treatment for opiate addiction reduces treatment
success, creating a need for eﬀective interventions. This review aimed to assess the eﬃcacy of contingency
management, a behavioural treatment that uses rewards to encourage desired behaviours, for treating non-
prescribed drug use during opiate addiction treatment.
Methods: A systematic search of the databases Embase, PsychInfo, PsychArticles and Medline from inception to
March 2015 was performed. Random eﬀects meta-analysis tested the use of contingency management to treat
the use of drugs during opiate addiction treatment, using either longest duration of abstinence (LDA) or per-
centage of negative samples (PNS). Random eﬀects moderator analyses were performed for six potential mod-
erators: drug targeted for intervention, decade in which the study was carried out, study quality, intervention
duration, type of reinforcer, and form of opiate treatment.
Results: The search returned 3860 papers; 22 studies met inclusion criteria and were meta-analysed. Follow-up
data was only available for three studies, so all analyses used end of treatment data. Contingency management
performed signiﬁcantly better than control in reducing drug use measured using LDA (d= 0.57, 95% CI:
0.42–0.72) or PNS (d= 0.41) (95% CI: 0.28–0.54). This was true for all drugs other than opiates. The only
signiﬁcant moderator was drug targeted (LDA: Q = 10.75, p= 0.03).
Conclusion: Contingency management appears to be eﬃcacious for treating most drug use during treatment for
opiate addiction. Further research is required to ascertain the full eﬀects of moderating variables, and longer
term eﬀects.
1. Introduction
Amongst those in treatment for opiate addiction, use of non-pre-
scribed drugs is very common. Hair samples from 99 recently deceased
opiate addiction patients identiﬁed a range of 21 diﬀerent drugs being
used during treatment, including cocaine, amphetamine, morphine and
diazepam (Nielsen et al., 2015). Other studies have observed that over a
third of patients entering opiate addiction treatment were also DSM-IV
dependent on a drug other than heroin (not including nicotine)
(Puigdollers et al., 2009), and poly drug use has been reported to be as
high as 68% (Taylor, 2015). These high levels of drug use are not
limited to illicit substances. Tobacco smoking is highly prevalent in
drug treatment in general (Cookson et al., 2014), with prevalence rates
of over 90% observed in individuals undergoing methadone treatment
for opiate addiction (Best et al., 2009; Clemmey et al., 1997). Metha-
done itself has been linked to increased tobacco cigarette consumption,
smoke intake and self-reported satisfaction of cigarette smoking (Chait
and Griﬃths, 1984), and to increased alcohol consumption compared
with heroin use (Backmund et al., 2003).
Use of non-prescribed drugs during methadone treatment for opiate
addiction has been associated with a range of adverse eﬀects such as
poor treatment retention and outcomes (Magura et al., 1998). Use of a
single drug during opiate addiction treatment is associated with a
threefold greater risk of dropping out of treatment, and use of multiple
drugs quadruples the risk of dropping out (White et al., 2014). For
example, cocaine use during methadone treatment has been linked to
persistence of heroin use (Hartel et al., 2011). Similarly, tobacco
smoking during opiate detoxiﬁcation results in signiﬁcantly greater
opiate craving and signiﬁcantly lower rates of detoxiﬁcation comple-
tion (Mannelli et al., 2013) and is associated with higher levels of illicit
drug use (Frosch et al., 2000).
High prevalence rates and the links to adverse treatment outcomes
indicate a need for eﬀective interventions for non-prescribed drug use
during opiate addiction treatment. One of the most widely used
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behavioural interventions is contingency management (CM). CM is
based on the theory of operant conditioning (Skinner, 1938), which
states that the administering of a reward for a particular behaviour
increases the likelihood of that behaviour being repeated. In the current
context, CM uses rewards (vouchers, clinical privileges or desirable
items to be won as prizes for example) to positively reinforce abstinence
from or reduced use of drugs during treatment for opiate addiction. CM
diﬀers from other common psychological interventions in that the focus
of treatment is not on introspective analysis of discrepancies between
goals and behaviour (as in motivational interviewing) or modiﬁcation
of ﬂawed cognitive processing (as in CBT), but instead on directly in-
ﬂuencing the reinforcement mechanisms involved in addiction
(Jhanjee, 2014). Previous reviews have shown CM to be moderately
eﬀective in treating substance use (illicit drugs, alcohol and tobacco)
disorders in general (Benishek et al., 2014; Davis et al., 2016; Dutra
et al., 2008; Lussier et al., 2006; Prendergast et al., 2006), particularly
so for opiate addiction (Prendergast et al., 2006). Despite a number of
recent reviews assessing the eﬃcacy of CM for substance use in general,
very little is known about the use of CM for treating use of non-pre-
scribed drugs in the context of opiate addiction treatment, where
treatment outcomes may diﬀer.
Whilst some of these reviews included studies assessing the use of
CM in this context (Benishek et al., 2014; Castells et al., 2009; Davis
et al., 2016; Lussier et al., 2006), none directly addressed the eﬃcacy of
CM for substance use during opiate addiction treatment. The most re-
cent review of this speciﬁc use of CM is a meta-analysis published over
16 years ago (Griﬃth et al., 2000). CM was observed to perform better
overall than control, and the eﬀects of CM for drug use during opiate
addiction treatment were observed to be moderated by ﬁve factors
(type of reinforcer, time to reinforcement delivery, targeted CM drug(s),
number of urine specimens collected per week and type of subject as-
signment). However, this review did not search the literature system-
atically, increasing the risk of bias in the selection of study data. Si-
milarly, it did not assess the eﬀects of diﬀerent drugs targeted with CM,
instead only assessing the moderating eﬀects of targeting single or poly
drug use. The aim of the present review was to assess the eﬃcacy of CM
for treating the use of diﬀerent non-prescribed drugs during treatment
for opiate addiction, by systematically searching the literature and as-
sessing the eﬀects of potentially moderating variables.
2. Method
A protocol for the current review is available online (see appendix
of Supplementary ﬁle).
2.1. Search strategy
The review was carried out in accordance with PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines
(Moher, 2009). Studies were identiﬁed using a keyword search of the
online databases Embase; PsychInfo; PsychArticles using the Ovid SP
interface and a MeSH search of Medline using the PubMed interface;
with the following search terms: “Contingency Management” or “Re-
ward” or “Payment” or “Incentive” or Prize” and “Substance” or
“Misuse” or “Drug” or “Narcotic*” or “Tobacco” or “Smok*” or “Sti-
mulan*” or “Cocaine” or “Alcohol” and “Opiate” or “Opioid” or
“Heroin” or “Methadone”. The search was limited to studies published
between each database’s inception and March 2015; published in the
English language and including only humans. See appendix1 for full
search strategy.
2.2. Inclusion and exclusion criteria
Studies were eligible for inclusion if they: i) Tested one or more CM
intervention(s) aimed at substance use reduction or abstinence in pa-
tients receiving treatment for opiate addiction. CM included any
intervention that consistently administered rewards to positively re-
inforce substance use reduction or abstinence in patients receiving
treatment for opiate addiction; ii) used a controlled trial design–either a
no/delayed treatment control group or an alternative therapy control
group, or controlled by repeated participation in two or more treatment
arms; iii) randomised participants to conditions; iv) provided re-
inforcement or punishment contingent on biological veriﬁcation of
substance use/abstinence; v) used consistent measures of substance use
at baseline and follow-up; vi) Published in a peer reviewed journal.
Studies were excluded if: i) Participation was non-voluntary – e.g.,
court orders, prison inmates etc.; ii) means and standard deviations for
treatment eﬀects were not available from the published data or the
authors.
2.3. Study selection
Studies were reviewed for inclusion by three independent re-
viewers, with all studies being reviewed for inclusion twice. TA pro-
cessed all titles and abstracts as ﬁrst reviewer, RC and LB jointly pro-
cessed half each as second reviewers. An agreement rate of 96% was
reached between reviewers; disagreements were discussed and resolved
by a separate reviewer, AM.
2.4. Quality assessment
The ‘Quality Assessment Tool for Quantitative Studies’ (Eﬀective
Public Health Practice Project, 2003) was used to assess the internal
and external validity of all studies, as well as any biases and confounds.
This assesses the quality of studies as strong, moderate or weak on six
domains (selection bias, study design, confounds, blinding, data col-
lection and withdrawals/dropouts), providing an overall score for the
quality of the evidence in the study. A study is rated as providing strong
evidence only when all domains are rated as moderate or strong, and a
moderate rating when strong or moderate ratings are achieved for all
bar one of the domains. Inter-rater reliability has been shown to be ‘fair’
across the six domains and ‘excellent’ overall, often performing better
than the Cochrane Collaboration Risk of Bias Tool (Armijo-Olivo et al.,
2012).
2.5. Data extraction and synthesis
All data extraction was completed by a single reviewer (TA) using
an extraction table designed speciﬁcally for the current review and
agreed by all reviewers (see supplementary materials). Where studies
did not contain means and standard deviations for treatment eﬀects,
authors were contacted up to two times to obtain the data. Requests for
data were sent to authors of 35 studies, with data for six studies being
received (Carpenedo et al., 2010; Downey et al., 2000; Epstein et al.,
2009; Kirby et al., 2013; Petry et al., 2007; Vandrey et al., 2007). Where
means and standard deviations were not obtained, alternative data in-
cluding F tests, t-tests and chi square were used to calculate an eﬀect
size where feasible (Dunn et al., 2010; Shoptaw et al., 2002; Silverman
et al., 1998, 1996).
2.6. Outcome measures
Standardised mean diﬀerences (Cohen’s d (Cohen, 1988)) were
calculated for each individual study using either: 1) longest duration of
abstinence (LDA) data or 2) percentage of biochemically veriﬁed ne-
gative samples (PNS). As follow-up data were available for only three of
the 10 studies that included a follow-up period, all data used in analyses
are those recorded during treatment.
2.7. Moderators
A number of possible moderators were assessed, based on those
T.S. Ainscough et al. Drug and Alcohol Dependence 178 (2017) 318–339
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shown in previous reviews to impact on the eﬃcacy of CM (Griﬃth
et al., 2000; Prendergast et al., 2006). These included the drug targeted
for intervention, the decade in which the study was carried out, the
quality of the study, duration of the intervention, the type of reinforcer
used, and the form of opiate treatment participants were undergoing.
Some moderators previously suggested to aﬀect the eﬃcacy of CM
(Griﬃth et al., 2000; Prendergast et al., 2006) could not be investigated
due to a lack of suitable data in the included studies or because all
studies used the same approach. For example, the number of times
abstinence was veriﬁed per week could not be investigated as 16 studies
recorded this three times a week compared to only ﬁve recording it
twice a week and one study recording it every day. Similarly, type of
incentive (positive, negative, mixed) was not tested as all bar two
studies in both analyses used a mixed incentive. Time to reinforcement
could not be tested as all included studies delivered immediate re-
inforcements.
2.8. Data analysis
Meta-analyses were carried out using RevMan v5.3 (Cochrane
Collaboration, 2014) software. Data were entered into a generic inverse
variance analysis in RevMan that analysed the eﬃcacy of CM compared
with control across all drug use during treatment for opiate addiction,
using both LDA and PNS. All meta-analyses were carried out as random
eﬀects analyses due to the wide variety of CM interventions included
(Riley et al., 2011). To allow comparison of CM to control, some multi-
Fig. 1. PRISMA ﬂow diagram.
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arm trials were collapsed into a two-arm design by averaging the eﬀects
across the treatment conditions (Cochrane Colaboration, 2011). This
was only done however when each arm used CM in isolation (other
than normal pharmacological treatment for opiate addiction); if a study
arm included CM in combination with another behavioural or phar-
macological treatment not part of standard treatment, then this arm
was not included in the meta-analysis. This was done in order to match
the design of the included studies with only single experimental and
control arms. Control arms were not collapsed unless each was a
standard treatment control. For example, one study (Schottenfeld et al.,
2005) had four conditions (CM with either methadone or buprenor-
phine and performance feedback with either methadone or buprenor-
phine), so the two CM conditions were collapsed together, as were the
two performance feedback conditions. Another study (Preston et al.,
2000) also had four conditions (CM, methadone increase, CM +me-
thadone increase and a usual care control), but no conditions were
collapsed and only the CM and usual care control conditions were used
in the analysis. The I2 statistic was used to assess the percentage of
variability in treatment eﬀect estimates attributable to between-study
heterogeneity.
Moderator analysis was performed using Comprehensive Meta-
analysis software V.3 (Borenstein et al., 2014). Results were computed
using random eﬀects statistics and indicate the extent to which each
moderator accounts for variability in eﬀect sizes with respect to drug
use outcomes. A signiﬁcant value of Q-between indicates signiﬁcant
diﬀerences among eﬀect sizes between the categories of the moderator
variable. This method also calculates the mean pooled eﬀect size for
each category within the moderator variable being tested and whether
this is signiﬁcant. For the drug targeted for intervention, studies fell
into ﬁve categories: opiates, cocaine, opiates and cocaine combined,
tobacco, and polysubstance use. For study decade, studies were grouped
as being published from 1990 to 1999, 2000 to 2009 and 2010 onwards
(study publication dates ranged from 1993 to 2015). Study quality
followed the strong, moderate and weak ratings of the ‘Quality As-
sessment Tool for Quantitative Studies’ (Eﬀective Public Health
Practice Project, 2003). Intervention durations were grouped as< 12
weeks, 12 weeks, and> 12 weeks. Reinforcer type was categorised as
monetary vouchers and ‘other’. Opiate treatment similarly contained
two categories, methadone treatment and ‘other’.
Publication bias was assessed using the ‘failsafe N’ technique
(Rosenthal, 1979), calculated using Comprehensive Meta-analysis
software V.3 (Borenstein et al., 2014). This calculates the number of
studies averaging a Z-value of zero that would be required to make the
overall pooled eﬀect size non-signiﬁcant (Rosenthal, 1979).
3. Results
3.1. Included studies
A total of 3144 studies were identiﬁed in the search, yielding a total
of 22 studies meeting inclusion criteria and included in the meta-ana-
lysis (Chutuape et al., 2001, 1999; Downey et al., 2000; Dunn et al.,
2010; Epstein et al., 2009, 2003; Gross et al., 2006; Katz et al., 2002a;
Katz et al., 2002b; Kidorf and Stitzer, 1993, 1996; Ling et al., 2013;
Peirce et al., 2006; Petry et al., 2014, 2007; Petry and Martin, 2002;
Preston et al., 2000; Schottenfeld et al., 2005; Silverman et al., 1998,
1996; Umbricht et al., 2014; Vandrey et al., 2007) (see PRISMA ﬂow
diagram, Fig. 1). The included studies randomised a total of 2333 pa-
tients to 39 CM conditions and 33 non-CM control conditions. This
included three studies with two CM conditions each collapsed into a
single CM condition, four studies with three CM conditions each col-
lapsed into a single CM condition, and two studies with two CM, and
two control, conditions each collapsed into single CM and control
conditions.
3.2. Study description and quality assessment
Eight of the 22 studies tested the eﬀects of CM for cocaine use, two
for opiate use, one for tobacco smoking, six for combined use of opiates
and cocaine and ﬁve for polysubstance use. Twenty-one studies
Table 2
EPHPP ratings for all included studies organised by drug target of CM intervention.
Study Selection Bias Study Design Confounds Blinding Data Collection Withdrawals/ Dropouts Overall
Cocaine
Epstein et al. (2003) 2 1 1 2 1 2 Strong
Katz et al. (2002a,b) 2 1 3 2 1 1 Moderate
Kidorf et al. (1993) 3 1 1 2 1 1 Moderate
Petry et al. (2007) 3 1 1 3 1 2 Weak
Silverman et al. (1996) 3 1 1 2 1 1 Moderate
Silverman et al. (1998) 2 1 1 2 1 3 Moderate
Umbricht et al. (2014) 3 1 1 1 1 2 Moderate
Vandrey et al. (2007) 3 1 3 2 1 3 Weak
Opiates
Ling et al. (2013) 2 1 3 2 1 2 Moderate
Preston et al. (2000) 3 1 3 1 1 1 Weak
Opiates and Cocaine
Chutuape et al. (2000) 3 1 1 2 1 3 Weak
Epstein et al. (2009) 3 1 1 2 1 2 Moderate
Groß et al. (2006) 3 1 1 2 1 2 Moderate
Katz et al. (2002a,b) 2 1 1 2 1 3 Moderate
Petry et al. (2002) 2 1 1 2 1 1 Strong
Schottenfeld et al. (2005) 3 1 1 1 1 3 Weak
Tobacco
Dunn et al. (2010) 2 1 1 3 1 2 Moderate
Poly-substance
Chutuape et al. (1999) 3 1 3 2 1 3 Weak
Downey et al. (2000) 3 3 3 2 1 3 Weak
Kidorf et al. (1996) 3 1 3 2 1 3 Weak
Peirce et al. (2006) 3 1 1 3 1 2 Weak
Petry et al. (2015) 3 1 1 2 1 3 Weak
1 = Strong, 2 = Moderate, 3 = Weak
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included some form of opiate substitution therapy (18 methadone, one
buprenorphine, one a mixed buprenorphine and naloxone tablet, and
one suboxone), with only a single study not utilising any form of opiate
substitution therapy. The duration of CM interventions used ranged
between 11 days and 31 weeks, with the number of participants in each
study ranging between 12 and 388. Seventeen studies reported reten-
tion rates, resulting in an average retention rate of 76.4% (range
51.2%–97.7%). All studies were carried out in the US, with 13 being
carried out in the same state (Maryland) (See Table 1 for full descrip-
tion of studies and interventions). Methodological quality assessment
rated two studies as overall providing strong evidence, 10 studies
moderate evidence and 10 studies weak evidence (Table 2).
3.3. Meta-Analysis
The meta-analysis for LDA (longest duration of abstinence) from all
substances combined contained 18 studies randomising 2059 patients
to 31 CM conditions and 25 non-CM control conditions. The random
eﬀects meta-analysis produced a pooled eﬀect size of d= 0.57 (95% CI:
0.42–0.72), with CM performing signiﬁcantly better than control
(Fig. 2). A moderate (Cochrane Colaboration, 2011) level of the
variability of eﬀects between studies was due to between-study
heterogeneity (I2 = 51%).
For PNS (percentage of negative samples), 12 studies randomising
1387 patients to 24 CM conditions and 21 non-CM control conditions
were included and the pooled eﬀect size was d= 0.41 (95% CI:
0.28–0.54), again with CM performing signiﬁcantly better than control
(Fig. 3). Variability of eﬀects was not due to between-study hetero-
geneity (I2 = 0%).
3.4. Moderator analysis
The only moderator found to have a signiﬁcant eﬀect on the eﬃcacy
of CM was intervention drug target, but only for LDA (Tables 3 and 4).
Within each of the categories of the six moderators, CM performed
signiﬁcantly better than control in all but three instances. Within drug
targeted for intervention, CM performed no better than control for
treating non-prescribed opiate use for both LDA and PNS. Within in-
tervention duration, CM failed to encourage signiﬁcantly better LDA
than control in studies with intervention duration of less than 12 weeks.
Within opiate treatment type, CM did not result in signiﬁcantly greater
PNS than control for studies where participants were in the ‘other’ ca-
tegory.
Fig. 2. Forest plot for LDA during treatment of all substances combined. (1) = Cocaine, (2) = opiates, (3) = opiates and cocaine, (4) = Tobacco, (5) = Poly-substance.
Fig. 3. Forest plot for PNS during treatment of all substances combined. (1) = Cocaine, (2) = opiates, (3) = opiates and cocaine, (4) = Tobacco, (5) = Poly-substance.
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3.5. Publication bias
There is widespread acceptance of the fact that studies reporting
positive results are far more likely to be published than studies re-
porting null ﬁndings, resulting in an over representation of positive
results within the literature (Rosenthal, 1991; Rosenthal and Rubin,
1988; Schmid, 2016). The ‘failsafe N’ (Rosenthal, 1979) calculates the
number of studies reporting null results that would be required to
overturn the statistically signiﬁcant diﬀerence between CM and control
observed above. For LDA, 560 papers reporting null results would be
required, and 101 for PNS.
Table 3
Random eﬀects moderator analysis results for LDA.
Moderator k1 Eﬀect Size (d)2 95% CI Z Value P value Q between (df)3 P of Q between
Drug targeted for intervention 18 10.75 (4) 0.03
Cocaine 6 0.75 0.45–1.04 4.91 < 0.001
Opiates 1 −0.10 −0.61–0.41 −0.40 0.70
Opiates and cocaine 6 0.48 0.32–0.64 5.85 < 0.001
Tobacco 1 1.02 0.37–1.67 3.10 < 0.01
Poly substance 4 0.62 0.27–0.98 3.45 < 0.01
Study decade 1.31 (2) 0.52
1990–1999 4 1.08 0.14–2.02 2.23 0.02
2000–2009 10 0.53 0.41–0.65 8.67 < 0.001
2010 onwards 4 0.53 0.32–0.74 4.92 < 0.001
Study Quality 2.66 (2) 0.23
Stong 2 0.87 0.48–1.27 4.37 < 0.001
Moderate 8 0.57 0.32–.82 4.47 < 0.01
Weak 8 0.51 0.30–0.72 4.75 < 0.001
Intervention Duration 1.30 (2) 0.52
< 12 Weeks 2 0.26 −0.41–0.93 0.77 0.44
12 Weeks 12 0.63 0.44–0.82 6.42 < 0.001
>12 Weeks 4 0.53 0.27–0.79 4.04 < 0.001
Reinforcer type 0.022 0.88
Monetary Vouchers 16 0.57 0.41–0.74 6.86 < 0.001
Other' 2 0.54 0.13–0.95 2.55 0.01
Opiate treatment 0.65 0.42
Methadone 13 0.61 0.42–0.80 6.45 < 0.001
Other 5 0.47 0.20–0.74 3.46 < 0.01
1Number of studies, 2Weighted random eﬀects, 3A signiﬁcant value of Q-between indicates signiﬁcant diﬀerences among eﬀect sizes between the categories of the moderator variable
Table 4
Random eﬀects moderator analysis results for PNS.
Moderator k1 Eﬀect Size (d)2 95% CI Z Value P value Q betweeen (df)3 P of Q between
Drug targeted for intervention 6.43 (4) 0.17
Cocaine 4 0.4 0.13–0.67 2.89 < 0.01
Opiates 3 0.18 −0.11–0.46 1.23 0.22
Opiates and cocaine 2 0.43 0.18–0.67 3.42 < 0.01
Tobacco 2 1.02 0.37–1.67 3.09 < 0.01
Poly substance 1 0.49 0.23–0.74 3.74 < 0.001
Study decade 1.10 (2) 0.58
1990–1999 2 0.51 0.25–0.77 3.83 < 0.001
2000–2009 3 0.30 0.01–0.59 2.01 0.05
2010 onwards 7 0.40 0.20–0.60 3.93 < 0.001
Study Quality 0.36 (2) 0.84
Stong 1 0.48 0.21–0.75 3.43 < 0.01
Moderate 5 0.36 0.06–0.66 2.32 0.02
Weak 6 0.44 0.30–0.58 0 < 0.001
Itntervention Duration 0.32 (2) 0.85
< 12 Weeks 5 0.47 0.28–0.67 4.73 < 0.001
12 Weeks 2 0.42 0.18–0.67 3.35 0.04
> 12 Weeks 5 0.37 0.02–0.71 2.06 < 0.01
Reinforcer type 0.41 (1) 0.52
Monetary Vouchers 9 0.39 0.23–0.54 4.82 < 0.001
Other' 3 0.51 0.17–0.85 2.94 < 0.01
Opiate treatment 0.35 (1) 0.55
Methadone 8 0.45 0.30–0.60 6.00 < 0.001
Other 4 0.32 −0.08–0.72 1.58 0.12
1Number of studies, 2Weighted random eﬀects, 3A signiﬁcant value of Q-between indicates signiﬁcant diﬀerences among eﬀect sizes between the categories of the moderator variable.
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4. Discussion
Overall, the random eﬀects analyses showed CM performed sig-
niﬁcantly better than control in encouraging abstinence from a range of
diﬀerent drugs in patients undergoing treatment for opiate addiction.
This was the case when measuring both LDA and PNS, producing
medium and small (Cohen, 1988) pooled eﬀect sizes respectively.
Moderator analysis performed on drug targeted for intervention, decade
in which the study was carried out, quality of the study, duration of the
intervention, type of reinforcer used, and form of opiate treatment,
showed drug target for LDA data to be the only characteristic sig-
niﬁcantly moderating the eﬃcacy of CM, driven primarily by the in-
eﬀectiveness of CM in treating opiate use. Despite only a single sig-
niﬁcant moderator eﬀect, within each of the six moderator categories
CM was found to perform signiﬁcantly better than control in all but
three cases. CM performed no better than control in encouraging ab-
stinence from non-prescribed opiates during treatment for opiate ad-
diction, measuring both LDA and PNS. CM also performed no better
than control for LDA in studies with interventions less than 12 weeks
long, and PNS in studies where usual opiate treatment was anything but
methadone treatment. CM for other non-prescribed drug use in treat-
ment for opiate addiction had no negative impact on usual treatment
retention compared to three-month follow-up retention rates observed
in usual opiate treatment (Burns et al., 2015; Hansen et al., 1990; Soyka
et al., 2008).
This review has a number of limitations. One aim of the moderator
analysis was to analyse the eﬀects of CM by target drug type. To im-
prove on the work of Griﬃth et al. (2000), ﬁve categories of drugs were
used rather than two. However, one of them, polysubstance use, com-
bined studies with four diﬀering deﬁnitions of this, making results hard
to integrate. CM still performed better in this category though, sug-
gesting a robustness of eﬀects across a variety of diﬀerent drug com-
binations. Another limitation is that the review does not contain any
grey literature. This means that any CM studies that have been con-
ducted yet never published are not included in the analysis.
The current review does have a number of strengths however. It is
the ﬁrst review in over 16 years to address directly the eﬃcacy of CM
for encouraging abstinence from non-prescribed drug use during
treatment for opiate addiction. This is important as CM has gained
considerable support in this time, having been recommended since
2007 as a treatment for drug misuse by the National Institute for Health
and Care Excellence (Pilling et al., 2007). The ﬁndings of the current
review support those of the previous reviews carried out in the ﬁeld;
ﬁnding an overall positive small to medium (Cohen, 1988) eﬀect size
for CM in treating drug use in opiate addiction treatment (Griﬃth et al.,
2000). This is in contrast to the usual small eﬀect size of psychological
interventions in the ﬁeld (Dutra et al., 2008). Findings of the present
review are also similar to those of a previous reviews assessing the use
of CM for drug use overall, regardless of treatment setting which found
similar small to medium eﬀect sizes for drug use in general (Benishek
et al., 2014; Castells et al., 2009; Davis et al., 2016; Lussier et al., 2006;
Prendergast et al., 2006). The robustness of the eﬀects of CM across
diﬀerent client groups suggests potential utility in treating a diverse
range of individuals and needs within the addictions ﬁeld.
We found no evidence of CM working better than control in en-
couraging abstinence from non-prescribed opiates during treatment,
which is in contrast to Prendergast et al. (2006) who identiﬁed CM as
one of the most eﬀective treatments for opiate use. The current review
included only two studies of this type, compared to four (diﬀerent)
studies included in the previous review because of diﬀering review
aims. Moreover, three of the four opiate studies in the previous review
systematically reduced methadone doses to zero over the course of the
intervention, thereby increasing the likelihood of relapse to opiates and
perhaps handing those receiving CM a competitive advantage over
those not. Studies in the current review however maintained medica-
tion doses throughout the duration of the intervention, possibly
eliminating this advantage and leading to the observed non-signiﬁcant
ﬁnding. With more data however, results for opiates may more closely
follow the trends observed with other drugs.
The moderator analysis performed in the current review has also
produced contradictory results to previous reviews. Previous reviews
(Griﬃth et al., 2000; Prendergast et al., 2006) found four of the six
moderators analysed here to have a signiﬁcant eﬀect on the eﬃcacy of
CM (drug targeted for intervention, the decade in which the study was
carried out, the quality of the study evidence, the length of the inter-
vention period). The current study only found a signiﬁcant eﬀect for
drug targeted for intervention however. A possible explanation for this
is diﬀerences in analysis, with the previous reviews adopting a ﬁxed
eﬀects analysis, and the current the more conservative and more widely
recommended (Cochrane Colaboration, 2011) random eﬀects analysis.
Support for this comes from more recent reviews that have adopted this
same random eﬀects analysis. Lussier et al. (2006) for example analysed
the eﬀects of three (drug targeted for intervention, the decade in which
the study was carried out, the quality of the study evidence) moderators
also analysed in the current and previous reviews, ﬁnding none of them
to have a signiﬁcant eﬀect.
More general limitations within the ﬁeld have also been identiﬁed,
for example a lack of data available for meta-analysis. In the current
review, a total of 21 studies that met all other inclusion criteria could
not be included in the quantitative data synthesis. This lack of available
data is even more pronounced for follow-up, with only 10 of the 22
included studies utilising some sort of follow-up element in their study
design, with data available for only three. CM is often criticised for poor
follow-up results, but given the paucity of data we were not able to
explore this here. Another concern is the quality of the studies included,
with only two studies being rated as providing strong evidence, and 20
papers providing weak evidence. Notably, every study in the current
review was performed in the US, with at least 13 performed in the same
state and 17 having at least one co-author from the same institution.
This signiﬁcantly limits the generalisability of the currently available
evidence on CM for non-prescribed drug use in opiate addiction treat-
ment.
This lack of evidence does however present avenues for future re-
search, particularly the use of CM for tobacco smoking in opiate ad-
diction treatment. This is especially relevant considering that tobacco
smoking is the most prevalent form of drug use in opiate addiction
treatment (Best et al., 2009; Clemmey et al., 1997), and it has been
shown that individuals in treatment for opiate addiction treatment have
a mortality rate four times that of non-smokers (Hser et al., 1994). It is
similarly important that future research studies are carried out in a
wider range of countries, include follow-ups to investigate relapse after
the removal of rewards, and focus on improving the overall quality of
the data that are published.
In conclusion, CM appears to be an eﬃcacious treatment of the use
of cocaine, non-prescribed opiates and cocaine, tobacco, and poly-
substance use during opiate addiction treatment, but not for use of non-
prescribed opiates. Evidence about longer-term eﬃcacy in this treat-
ment context remains lacking, as is research into the eﬀects of CM on
tobacco, the most prevalent secondary addiction in this population.
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